Scinai Immunotherapeutics (SCNI) Operating Expenses (2014 - 2026)

Scinai Immunotherapeutics (SCNI) has 13 years of Operating Expenses data on file, last reported at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 24.89% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$3.8 million (down 188.65% YoY), and the FY2025 full-year result was -$5.4 million, down 167.15% from the prior year.
• Operating Expenses eased to -$1.3 million in Q1 2026, from -$697000.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $17.6 million in Q4 2023 to a low of -$14.8 million in Q3 2022.
• A 5-year average of $2.1 million and a median of $1.9 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 159.81% in 2023 and plunged 320.39% in 2024, its largest moves.
• Tracing SCNI's Operating Expenses over 5 years: stood at $6.8 million in 2022, then jumped by 159.81% to $17.6 million in 2023, then declined by 20.29% to $14.0 million in 2024, then tumbled by 104.97% to -$697000.0 in 2025, then sank by 93.54% to -$1.3 million in 2026.
• Business Quant data shows SCNI's Operating Expenses at -$1.3 million in Q1 2026, -$697000.0 in Q2 2025, and -$1.8 million in Q1 2025.